Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Japan Tissue Engineering Co., Ltd. ( (JP:7774) ) is now available.
Japan Tissue Engineering Co., Ltd. has received approval for the expanded use of its autologous cultured cartilage product, JACC, for treating osteoarthritis. This approval marks a significant advancement in addressing the challenges of cartilage regeneration, offering a new treatment option for patients who do not respond to conventional therapies. J-TEC plans to make JACC available to eligible patients soon and aims for insurance coverage by December 2025, potentially impacting the treatment landscape for osteoarthritis in Japan.
More about Japan Tissue Engineering Co., Ltd.
Japan Tissue Engineering Co., Ltd. (J-TEC) is a pioneer in regenerative medicine in Japan, focusing on developing innovative solutions to address unmet medical needs worldwide. The company specializes in creating autologous cultured tissues, such as their product JACC, which is used for cartilage repair.
Average Trading Volume: 284,887
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen25.46B
For detailed information about 7774 stock, go to TipRanks’ Stock Analysis page.